research use only
Cat.No.S5260
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Endogenous Metabolite Inhibitors | 4-HNE (4-Hydroxynonenal) Heparan Sulfate Oleic acid (cis-9-Octadecenoic acid) Ademetionine (S-Adenosylmethionine) Sodium L-lactate 3-Hydroxybutyric acid (BHB acid) |
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 507.18 | Formula | C10H16N5O13P3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 56-65-5 | -- | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| In vitro |
ATP, a multifunctional nucleoside triphosphate and an important endogenous signaling molecule, restores signaling responses to anti-TCR treatment in Jurkat cells. |
|---|---|
| In vivo |
ATP can activate the NLRP3 inflammasome and enhance the production of pro-inflammatory cytokines, thus protecting mice against bacterial infection. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-09-04)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07354347 | RECRUITING | Heart Disease; Implantable Cardioverter Defibrillator (ICD); Heart Rhythm Disorders; Ventricular Tachyarrhythmias |
Rigshospitalet, Denmark |
2026-02-01 | |
| NCT06924073 | RECRUITING | Adolescent HIV Infection; Transition to Adult Care; Implementation Science; Implementation Strategies |
University of Washington |
2025-10-16 | |
| NCT06942572 | RECRUITING | Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy |
Splice Bio |
2025-02-11 | PHASE1; PHASE2 |
| NCT07167966 | ENROLLING_BY_INVITATION | Preclinical Alzheimer's Disease; Prodromal Alzheimer's Disease; Alzheimer Disease |
Paul S. Aisen |
2026-11-03 | PHASE2 |
| NCT06921720 | RECRUITING | Phosphate Diabetes; X-linked Hypophosphatemia |
Hospices Civils de Lyon |
2025-05-16 | |
| NCT07296354 | NOT_YET_RECRUITING | Neuropathic Pain |
Egyptian International Pharmaceutical Industries Co |
2026-01-10 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.